Vascular dementia:: Distinguishing characteristics, treatment, and prevention

被引:147
作者
Román, GC
机构
[1] Univ Texas, Hlth Sci Ctr, Sch Med, Dept Med,Div Neurol, San Antonio, TX 78229 USA
[2] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78229 USA
关键词
vascular dementia; poststroke dementia; multi-infarct dementia; strategic stroke dementia; subcortical ischemia dementia;
D O I
10.1046/j.1532-5415.5155.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Vascular dementia (VaD) is the second-most-common cause of dementia in the elderly, after Alzheimer's disease (AD). VaD is defined as loss of cognitive function resulting from ischemic, hypoperfusive, or hemorrhagic brain lesions due to cerebrovascular disease or cardiovascular pathology. Diagnosis requires the following criteria: cognitive loss, often predominantly subcortical; vascular brain lesions demonstrated by imaging; a temporal link between stroke and dementia; and exclusion of other causes of dementia. Poststroke VaD may be caused by large-vessel disease with multiple strokes (multiinfarct dementia) or by a single stroke (strategic stroke VaD). A common form is sub. cortical ischemic VaD caused by small-vessel occlusions with multiple lacunas and by hypoperfusive lesions resulting from stenosis of medullary arterioles, as in Binswanger's disease. Unlike with AD, in VaD, executive dysfunction is commonly seen, but memory impairment is mild or may not even be present. The cholinesterase inhibitors used for AD are also useful in VaD. Prevention strategies should focus on reduction of stroke and cardiovascular disease, with attention to control of risk factors such as hypertension, diabetes mellitus, hypercholesterolemia, and hyperhomocysteinemia.
引用
收藏
页码:S296 / S304
页数:9
相关论文
共 70 条
[1]  
Alzheimer A, 1894, NEUROLOGISCHES ZENTR, V13, P765
[2]  
Alzheimer A., 1907, ALLG Z PSYCHIAT, V64, P146, DOI DOI 10.1002/CA.980080612
[3]  
[Anonymous], 2002, B WORLD HEALTH ORGAN, V80, P764
[4]   Poststroke dementia -: Clinical features and risk factors [J].
Barba, R ;
Martínez-Espinosa, S ;
Rodríguez-García, E ;
Pondal, M ;
Vivancos, J ;
Del Ser, T .
STROKE, 2000, 31 (07) :1494-1501
[5]  
Binswanger O, 1894, BERL KLIN WOCHENSCHR, V31
[6]  
Binswanger O Ludwig., 1894, BERL KLIN WOCHENSCHR, V31, P1103
[7]  
Binswanger OLudwig, 1894, BERL KLIN WOCHENSCHR, V31, P1137
[8]  
BLACK S, 2003, IN PRESS STROKE
[9]   Stroke, statins, and cholesterol - A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors [J].
Blauw, GJ ;
Lagaay, AM ;
Smelt, AHM ;
Westendorp, RGJ .
STROKE, 1997, 28 (05) :946-950
[10]   Progress in reducing the burden of stroke [J].
Chalmers, J ;
Chapman, N .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2001, 28 (12) :1091-1095